Regen BioPharma Financials
| RGBP Stock | USD 0.06 0 8.17% |
Regen |
Regen BioPharma Stock Summary
Regen BioPharma competes with Creative Medical, Sonnet Biotherapeutics, Pharmather Holdings, Regen BioPharma, and Ascletis Pharma. Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. Regen BioPharma, Inc. was incorporated in 2012 and is based in La Mesa, California. Regen Biopharma operates under Biotechnology classification in the United States and is traded on OTC Exchange.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US75886M1027 |
| Business Address | 4700 Spring Street, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | regenbiopharmainc.com |
| Phone | 619 722 5505 |
| Currency | USD - US Dollar |
Regen BioPharma Key Financial Ratios
Regen BioPharma's financial ratios allow both analysts and investors to convert raw data from Regen BioPharma's financial statements into concise, actionable information that can be used to evaluate the performance of Regen BioPharma over time and compare it to other companies across industries.| Return On Asset | -0.76 | |||
| Beta | 3.36 | |||
| Z Score | -26.6 |
Regen Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Regen BioPharma's current stock value. Our valuation model uses many indicators to compare Regen BioPharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Regen BioPharma competition to find correlations between indicators driving Regen BioPharma's intrinsic value. More Info.Regen BioPharma is rated second in return on asset category among its peers. It is rated third in profit margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Regen BioPharma's earnings, one of the primary drivers of an investment's value.Regen BioPharma Systematic Risk
Regen BioPharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Regen BioPharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Regen BioPharma correlated with the market. If Beta is less than 0 Regen BioPharma generally moves in the opposite direction as compared to the market. If Regen BioPharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Regen BioPharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Regen BioPharma is generally in the same direction as the market. If Beta > 1 Regen BioPharma moves generally in the same direction as, but more than the movement of the benchmark.
Regen BioPharma December 3, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Regen BioPharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Regen BioPharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Regen BioPharma based on widely used predictive technical indicators. In general, we focus on analyzing Regen Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Regen BioPharma's daily price indicators and compare them against related drivers.
| Downside Deviation | 26.29 | |||
| Information Ratio | 0.1015 | |||
| Maximum Drawdown | 196.39 | |||
| Value At Risk | (47.83) | |||
| Potential Upside | 100.0 |
Additional Tools for Regen Pink Sheet Analysis
When running Regen BioPharma's price analysis, check to measure Regen BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regen BioPharma is operating at the current time. Most of Regen BioPharma's value examination focuses on studying past and present price action to predict the probability of Regen BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regen BioPharma's price. Additionally, you may evaluate how the addition of Regen BioPharma to your portfolios can decrease your overall portfolio volatility.